نبذة مختصرة : Aim: COVID-19 has been associated with dysregulated immune responses, with increasing evidence indicating sustained inflammasome activation and subsequent pro-inflammatory cytokine production. This study aimed to characterize the temporal profile of inflammatory markers, particularly interleukin (IL)-1β, in post-COVID-19 patients compared with pre-pandemic healthy controls, using data from the Psychiatric Symptoms for COVID-19 Registry Japan (PSCORE-J).
Methods: Blood samples were analyzed from 119 post-COVID-19 patients (median age 45 years) recruited during 2023 and 374 pre-pandemic healthy controls (median age 65 years). For post-COVID-19 patients, samples were collected at baseline, 3 months, and 9 months. Multiple inflammatory markers were assessed, including IL-1β, IL-6, IL-8, IL-10, IL-12, TNF-α, IFN-γ, IFN-β, IP-10, ACE2, and eotaxin. Age- and sex-adjusted analyses were performed on log-transformed IL-1β levels.
Results: IL-1β levels were significantly elevated in post-COVID-19 patients compared with healthy controls across all age groups (under 30s: 0.69 ± 0.33 vs. 0.25 ± 0.03; 30s: 0.70 ± 0.63 vs. 0.26 ± 0.09; 40s: 0.84 ± 0.76 vs. 0.30 ± 0.23; 50s: 0.67 ± 0.65 vs. 0.26 ± 0.10; 60 or over: 0.54 ± 0.30 vs. 0.26 ± 0.23 pg/mL). This elevation was sustained throughout the 9-month follow-up (baseline: 0.500 [0.33-0.890]; 3 months: 0.630 [0.28-1.290]; 9 months: 0.54 [0.29-0.96] pg/mL) compared with controls (0.24 [0.21-0.27] pg/mL). Other inflammatory markers showed either no significant differences or were paradoxically lower in patients.
Conclusion: SARS-CoV-2 infection is associated with persistent elevation of IL-1β levels that remains stable over a 9-month period, suggesting sustained inflammasome activation. These findings provide novel insight into post-COVID-19 inflammatory processes and may have important implications for understanding both acute and chronic manifestations of the disease.
Trial Registration: Japan Registry of Clinical Trials: jRCT1030220711.
(© 2026 The Author(s). Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.)
References: World Health Organization (WHO), Post COVID‐19 Condition (Long COVID) (WHO, 2022), https://www.who.int/europe/news‐room/fact‐sheets/item/post‐covid‐19‐condition.
C. Fernandez‐De‐Las‐Peñas, K. I. Notarte, R. Macasaet, et al., “Persistence of Post‐COVID Symptoms in the General Population Two Years After SARS‐CoV‐2 Infection: A Systematic Review and Meta‐Analysis,” Journal of Infection 88, no. 2 (2024): 77–88.
M. Cai, Y. Xie, E. J. Topol, and Z. Al‐Aly, “Three‐Year Outcomes of Post‐Acute Sequelae of COVID‐19,” Nature Medicine 30, no. 6 (2024): 1564–1573.
T. Chen, C. Chang, and P. Hung, “Possible Pathogenesis and Prevention of Long COVID: SARS‐CoV‐2‐Induced Mitochondrial Disorder,” International Journal of Molecular Sciences 24, no. 9 (2023): 8034.
T. S. Rodrigues, K. S. De Sá, A. Y. Ishimoto, et al., “Inflammasomes Are Activated in Response to SARS‐CoV‐2 Infection and Are Associated With COVID‐19 Severity in Patients,” Journal of Experimental Medicine 218, no. 3 (2021): e20201707.
R. Hadad, R. W. Keane, and J. P. De Rivero Vaccari, “Inflammasome Signaling Proteins as Biomarkers of COVID‐19,” Frontiers in Immunology 14 (2023): 1014665.
PSCORE‐J Psychiatric Symptoms for COVID‐19 Registry Japan (National Center of Neurology and Psychiatry, 2022), https://pscore‐j.ncnp.go.jp.
E. Bagarinao, H. Watanabe, S. Maesawa, et al., “An Unbiased Data‐Driven Age‐Related Structural Brain Parcellation for the Identification of Intrinsic Brain Volume Changes Over the Adult Lifespan,” NeuroImage 169 (2018): 134–144.
A. Abbate, S. Toldo, C. Marchetti, J. Kron, B. W. van Tassell, and C. A. Dinarello, “Interleukin‐1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease,” Circulation Research 126, no. 9 (2020): 1260–1280.
F. L. van de Veerdonk, M. G. Netea, C. A. Dinarello, and L. A. B. Joosten, “Inflammasome Activation and IL‐1β and IL‐18 Processing During Infection,” Trends in Immunology 32, no. 3 (2011): 110–116.
J. G. Cheong, A. Ravishankar, S. Sharma, et al., “Epigenetic Reprogramming of Innate Immunity in Long COVID,” Cell 186, no. 14 (2023): 2948–2961.
E. Lobanova, S. V. Antonyuk, N. D. Telling, et al., “ASC Specks as a Single‐Molecule Fluid Biomarker of Inflammation,” Nature Communications 15 (2024): 9690.
R. Klein, A. Vanderheiden, A. Nordvig, et al., “COVID‐19 Induces CNS Cytokine Expression and Loss of Hippocampal Neurogenesis,” Brain 145, no. 12 (2022): 4193–4201.
L. Müller and S. Di Benedetto, “The Impact of COVID‐19 on Accelerating of Immunosenescence and Brain Aging,” Frontiers in Cellular Neuroscience 18 (2024): 1471192.
H. C. Lasseter, A. C. Provost, V. Blanchard, et al., “Cross‐Platform Comparison of Highly Sensitive Immunoassay Technologies to Assess Cytokine Markers in Human Serum and Plasma,” PLoS One 15, no. 2 (2020): e0229565.
H. J. Lachmann, P. Lowe, S. D. Felix, et al., “In Vivo Regulation of Interleukin‐1β in Patients With Cryopyrin‐Associated Periodic Syndromes,” Journal of Experimental Medicine 206, no. 5 (2009): 1029–1036.
D. M. Rissin, C. W. Kan, T. G. Campbell, et al., “Single‐Molecule Enzyme‐Linked Immunosorbent Assay Detects Serum Proteins at Subfemtomolar Concentrations,” Nature Biotechnology 28, no. 6 (2010): 595–599.
O. J. McElvaney, N. L. McEvoy, O. F. McElvaney, et al., “Characterization of the Inflammatory Response to Severe COVID‐19 Illness,” American Journal of Respiratory and Critical Care Medicine 202, no. 6 (2020): 812–821.
M. Jahid, Rehan‐Ul‐Haq, D. Chawla, R. Avasthi, and R. S. Ahmed, “Association of Polymorphic Variants in IL1B Gene With Secretion of IL‐1β Protein and Inflammatory Markers in North Indian Rheumatoid Arthritis Patients,” Gene 641 (2018): 63–67.
A. B. S. Maciel, A. S. Pinto, B. M. Silva, et al., “Inflammatory Discoveries Two Years After Acute Severe COVID‐19: A Longitudinal Biomarker Profile Assessment in Long COVID Individuals in the Brazilian Amazon,” Frontiers in Immunology 15 (2024): 1520193.
Processing Request
No Comments.